We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Skinbiotherapeutics Plc | LSE:SBTX | London | Ordinary Share | GB00BF33H870 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 9.25 | 9.00 | 9.50 | 9.25 | 9.25 | 9.25 | 59,297 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 132k | -2.84M | -0.0163 | -5.67 | 16.1M |
Date | Subject | Author | Discuss |
---|---|---|---|
06/2/2018 10:41 | Buying at 8.2p! Had to grab a few more. | jestercat2 | |
06/2/2018 10:26 | ps .. didn't mean to sound patronizing there | onedayrodders | |
06/2/2018 09:08 | Dr.Cath will be promoting the business at four events between later this month and early March prior to the human trials of the cosmetic cream. Perhaps more news releases coming our way soon imo. SBTX is a gift at these discounted prices. | bobalot | |
06/2/2018 08:55 | Crazy over-reaction. Just bought 31K at 8.2p! My lowest purchase price of SBTX. | parob | |
01/2/2018 15:42 | These events and publications are worth tracking: Dr. Cath is a speaker at the European event being held in Holland: Microbiome R&D and Business Collaboration Forum: Europe 21st-22nd Mar 2018. Microbiome Futures is a landmark event that will document the future of microbiome research and commercialisation. A half day panel discussion – reporting on KOL research and audience consultation 250 participants from leading companies and institutions Outcomes to be published in Nature Biotechnology Gala networking dinner The live event, on May 23, will be the culmination of a thorough research process during which the working group will be gathering input from a global pool of stakeholders in the microbiome space. They will come prepared, having researched and discussed issues from the science of moving from correlation to causation to practical solutions to data and regulatory hurdles. | bobalot | |
01/2/2018 06:44 | Cath is well known to several global players as she has researched and tested for boots and j and j I believe. I'm terry sure they are being kept in the loop on progress. Cap way too low for me. Just needs volume so happy to buy when it's quiet when funds allow. | shrewdmole | |
01/2/2018 06:42 | The organisers of the conference said:"Following the mainstream focus on the gut microbiome and its role in health and disease, researchers and industry experts are now turning their attention towards the emerging relationship between the skin microbiome and healthy skin. This has the potential to revolutionise the beauty and personal care industry," | parob | |
31/1/2018 22:13 | Interest building in the sector. Think this is the first conference I’ve seen specifically for the skin microbiome sector: Skin Microbiome Conference set for May 2018 31-Jan-2018 | parob | |
31/1/2018 12:27 | Shook the piggy bank and just grabbed 35k at 8.75p. Great price. | zedder | |
30/1/2018 19:00 | From their twitter:Company CEO Cath O'Neill is to present at the Shares Investor Evenings in Manchester (20 Feb 2018) and Edinburgh (28 Feb 2018) where she'll be talking about SkinBioTherapeutics' history and strategy for 2018.It was a company presentation that ignited the N4P share price. Hopefully the same will happen here!! | parob | |
30/1/2018 18:44 | Thanks Bobalot - wasn't aware of that - reassuring! | jestercat2 | |
30/1/2018 17:05 | The next news will come from a presentation from SBTX towards the end of February where Dr. Cath/ CEO will explain the schedule going forward...so clearly the schedule has changed and is probably going to be accelerated by bringing developments forward. THUS NOTHING TO FEAR -- this is a better investment than most that is highly likely to give excellent returns for investors. | bobalot | |
30/1/2018 15:55 | Bobalot - is that the next 'expected' news? All gone rather quiet here. Is there anything else likely in the pipeline before May? If not I fear for the share price in the meantime. | jestercat2 | |
30/1/2018 13:20 | SkinBio is not far behind the commercialization curve for its cosmetic cream because human testing starts Q2/2018 -- possibly April and if it provides proof of purpose the commercial partner who has been showing interest since last September is highly likely to use the SkinBio product. The Human Trials will only take a month followed by assessment. We could get all the results and analysis in by mid May imo. It is worth noting the cosmetic cream has already been tested on live skin during development. There are about three major players in the market so far including SBTX so its still early doors for what will become a massive market change for the cosmetics industry. | bobalot | |
30/1/2018 10:52 | Interesting article. I like how it talks to skin microbiome being on trend for 2018. But it also looks a like a decent competitor on the cosmetics front. It also talks to applying their science to acne and eczema, similar to SBTX plans. On the downside they clearly have a headstart and now have Unilever backing. Cosmetics will be all about the marketing to get the attention followed by user experience of the product. It will be interesting to see how SBTX product is marketed. Getting a big player to sell and market will also determine success. Looking at Gallinée website they tell a nice story. But as you say, the attractive message here is that other big players will be looking to get into the skin microbiome trend! | toadhall1 | |
30/1/2018 08:03 | Another nibble for me whilst it's under the IPO price. Some of the biggest global companies are now moving into this space. Unilever Ventures takes minority stake in microbiome beauty start-up Gallinée 29/1/18 | parob | |
26/1/2018 23:16 | I've had him on filter for ages, after his n'enth meaningless post. He must like talking to himself?? Anyway, just wanted to say, nice weather in Surrey, while we wait for any interesting news. John | 2350220 | |
26/1/2018 16:26 | Here is the latest edition of the magazine: Well worth a read imo. | bobalot | |
26/1/2018 16:23 | Here is a very interesting sector development. Researchers Discover 10 New Immune Systems in Bacteria The findings more than double the number of known defense mechanisms, piquing the interests of molecular biology tool developers. By Jim Daley | January 25, 2018 | bobalot | |
26/1/2018 13:49 | Now that's a thought owenmo, I wonder if SoH's team might develop microbiome for treating OCD !! John | 2350220 | |
26/1/2018 12:21 | elrico 25 Jan '18 - 15:47 - 1265 of 1268 (Filtered) WHAT AN IDIOT AND WHAT A RAMPER. | bobalot | |
25/1/2018 18:57 | Obsessive compulsive disorder (OCD) - in three little words. | owenmo | |
25/1/2018 16:42 | I see what you me, all posted several times before and by the same hand. The joys of spare time. :( | incanus |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions